Skip to main content
NCBI home page
Springer logoLink to Springer
. 2015 Mar 10;24(7):3047–3061. doi: 10.1007/s00044-015-1360-6

Synthesis and anticonvulsant activity of new N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide derivatives

Krzysztof Kamiński 1,✉, Beata Wiklik 1, Jolanta Obniska 1
PMCID: PMC4491109  PMID: 26167103

Abstract

Twenty-two new N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide derivatives have been synthesized and evaluated for their anticonvulsant activity in animal models of epilepsy. These molecules have been designed as analogs of previously obtained anticonvulsant active pyrrolidine-2,5-diones in which heterocyclic imide ring has been changed into chain amide bound. The final compounds were synthesized in the alkylation reaction of the corresponding amines with the previously obtained alkylating reagents 2-chloro-1-(3-chlorophenyl)ethanone (1) or 2-chloro-1-[3-(trifluoromethyl)phenyl]ethanone (2). Initial anticonvulsant screening was performed using standard maximal electroshock (MES) and subcutaneous pentylenetetrazole screens in mice and/or rats. Several compounds were tested additionally in the psychomotor seizures (6-Hz model). The acute neurological toxicity was determined applying the rotarod test. The results of pharmacological studies showed activity exclusively in the MES seizures especially for 3-(trifluoromethyl)anilide derivatives, whereas majority of 3-chloroanilide analogs were inactive. It should be emphasize that several molecules showed also activity in the 6-Hz screen which is an animal model of human partial and therapy-resistant epilepsy. In the in vitro studies, the most potent derivative 20 was observed as moderate binder to the neuronal voltage-sensitive sodium channels (site 2). The SAR studies for anticonvulsant activity confirmed the crucial role of pyrrolidine-2,5-dione core fragment for anticonvulsant activity.

Keywords: Phenylacetamides, Anticonvulsant activity, SAR studies, In vivo studies, In vitro studies, Epilepsy

Introduction

Epilepsy is one of the most prevalent neurological disorders, affecting approximately 0.5–1 % people worldwide. It has a chronic and progressive nature, characterized by recurring seizures of various manifestations. The basic method of the treatment of epilepsy is pharmacotherapy. It is a symptomatic treatment which allows abolishing or reducing the number of seizure episodes, however, does not inhibit the pathophysiological processes of epileptogenesis and does not eliminate organic changes in the central nervous system (CNS), which are the underlying causes of the disease. In about 25 % of patients, the desired results cannot be achieved with the use of pharmacotherapy, this form of disease is known as refractory epilepsy, the treatment of which is based on surgical vagus nerve stimulation (WHO, 2010; Bell and Sander, 2002; Chang and Lowenstein, 2003). The variety of molecular targets, not always precisely definite, makes it difficult to establish an unequivocal mechanism of action of anti-epileptic drugs (AEDs). This fact is also reflected in the limited possibilities of designing new drugs on the base of the structure of a given biological target. Therefore, currently, there are two different methods of search for new anticonvulsants: modifications of clinically effective AEDs or synthesis of entirely new structures (Khan et al., 2012). Taking into consideration the above limitations, many authors conducted attempts to identify the structural features crucial for anticonvulsant activity. On the basis of these researches, several pharmacophoric models, enabling a more rational design of new anticonvulsants, have been described. Thus, one of the important core fragments of anticonvulsants is defined by nitrogen heterocyclic system, usually imide or lactam and phenyl or alkyl groups attached to the heterocyclic system (Wong et al., 1986; Bruno-Blanch et al., 2003; Malawska, 2005). This common template is present in the structures of old, however well-established AEDs, such as ethosuximide and phenytoin as well as among the newest drugs, e.g., levetiracetam, brivaracetam or seletracetam (Rogawski and Porter, 1990; Bialer et al., 2007) (Fig. 1).

Fig. 1.

Fig. 1

Open in a new tab

Structures of known AEDs containing nitrogen heterocyclic ring

Bearing in mind the aforementioned, in our laboratory, since many years we have been conducting studies in the group of pyrrolidine-2,5-dione derivatives differently substituted at the imide nitrogen atom as well as at the 3-position of the heterocyclic ring as candidates on new AEDs. Many of these compounds were highly effective in the animal models of epilepsy (Kamiński et al., 2014, 2013, 2011a, b; Obniska et al., 2013, 2010; Obniska and Zagórska, 2003). Structures and designated median effective doses (ED50) in the maximal electroshock (MES) seizure test for the model pyrrolidine-2,5-diones obtained in former research (Obniska et al., 2013) are shown in Fig. 2.

Fig. 2.

Fig. 2

Open in a new tab

Structures of model pyrrolidine-2,5-diones obtained in the previous research

Another important structural fragment of many anticonvulsants as well as compounds being currently in clinical trials is an amide moiety presented in a chain form (Bruno-Blanch et al., 2003; Hadjipavlou-Litina, 1998; Luszczki, 2009; Hen et al., 2010; Morieux et al., 2008; Ghidini et al., 2006; Beguin et al., 2003; Masereel et al., 2002). It should be stressed that this chemical structure possessed several the newest AEDs such as lacosamide (chemically the functionalized amino acid) or valrocemide and valnoctamide which are the unteratogenic derivatives of valproic acid (Fig. 3).

Fig. 3.

Fig. 3

Open in a new tab

Structures of known AEDs containing chain amide bound

Taking into consideration the above findings in the current studies, we have focused on synthesis of new N-phenylacetamide derivatives as targets for new AEDs. These compounds were designed as analogs of corresponding pyrrolidine-2,5-dine derivatives, which showed high anticonvulsant activity in the animal models of epilepsy (Obniska et al., 2010). The main modification relied on the change of imide ring into chain amide bound (Fig. 4). Therefore, the aim of the current studies was to elucidate how the structure of imide/amide fragment affects anticonvulsant activity.

Fig. 4.

Fig. 4

Open in a new tab

The exchange of the pyrrolidine-2,5-dione core fragment for chain amide bound

Results and discussion

Chemistry

The synthesis of compounds 3–24 was accomplished as shown in Scheme 1. The starting materials 2-chloro-1-(3-chlorophenyl)ethanone (1) and 2-chloro-1-[3-(trifluoromethyl)phenyl]ethanone (2) were prepared by acylation of 3-chloroaniline or 3-trifluoromethylaniline with 2-chloroacetyl chloride. The reaction was carried out at 0 °C for 3 h in the mixture consisted of dichloromethane (DCM) and 2 % aqueous sodium hydroxide solution. The final compounds 3–24 were synthesized in the alkylation reaction of the corresponding amines with the previously obtained alkylating reagents 1 and 2. The reaction was carried out at a temperature of 60 °C in a biphasic liquid–solid system consisting of dry acetone, potassium carbonate and catalytic amount of potassium iodide. The progress of the reaction was monitored using HPLC chromatography. Compounds 3–24 were obtained in yields ranging from 44 to 78 %. Their purities were assessed by HPLC chromatography (the HPLC chromatogram of 22 is shown in Fig. 5). The final compounds were fully characterized by elemental analyses (C, H, N) and 1H NMR, 13C NMR, 19F NMR, LC/MS spectra. The detailed physicochemical and analytical data are listed in the experimental section.

Scheme 1.

Scheme 1

Open in a new tab

Synthetic pathways of intermediates 1, 2 and target compounds 3–24

Fig. 5.

Fig. 5

Open in a new tab

The HPLC chromatogram of compound 22

The 1H NMR spectrum of compound 3 displayed several proton chemical shifts consistent with the proposed structure. The eight protons of piperazine moiety were observed as broad multiplet (δ 3.06–3.93 ppm). The methylene linker at the acetamide fragment occurred as singlet at δ 4.33 ppm. The aromatic protons were observed at the expected chemical shifts as six multiplets within the range of δ 6.81–7.86 ppm. The amide (NH) proton appeared as broad singlet at δ 10.86 ppm. The proton of protonated piperazine fragment (+NH) was observed as broad singlet at δ 11.55 ppm. The 13C NMR spectrum of 3 showed four peaks at δ 51.3, 51.9, 52.5 and 53.3 ppm which correspond to carbon atoms of piperazine ring. The carbon atom of the methylene linker at the acetamide fragment occurred as peak at δ 54.1 ppm. The peaks of carbon atoms of the aromatic rings were detected at the expected chemical shifts within the range δ 111.7–146.3 ppm. The peak at 172.1 ppm was ascribed to a carbon in a carbonyl group.

The 1H NMR spectrum of 13 revealed two multiplets within the range of δ 1.59–1.88 and 2.96–3.56 ppm which were ascribed to eight protons of the morpholine ring. The methylene linker at the acetamide fragment occurred as singlet at δ 4.15 ppm. Four aromatic protons gave three multiplets and on triplet within the range of δ 7.13–7.86 ppm. The amide (NH) proton appeared as broad singlet at δ 10.05 ppm. The proton of protonated morpholine fragment (+NH) was observed as broad singlet at δ 11.41 ppm. The 13C NMR spectrum of 13 showed five peaks at δ 51.8, 52.6, 53.2, 67.8 and 68.6 ppm which correspond to carbon atoms of morpholine ring and the methylene linker at the acetamide fragment. The aromatic carbons in the benzene ring were observed as six peaks within the range δ 117.8–138.1 ppm. The peak at 171.5 ppm was ascribed to a carbon in a carbonyl group.

Anticonvulsant activity

The preclinical development of new chemical agents for the treatment of epilepsy is based on the use of predictable animal seizure models, which correspond to different types of human epilepsies. Despite the diversity of models that could potentially be used to screen for anticonvulsant activity, the MES model and the subcutaneous pentylenetetrazole (scPTZ) model remain the “gold standards” in the early stages of testing. The MES test is the mechanism-independent animal seizure model which enables identification of compounds preventing seizure spread. This test uses an electrical stimulus to produce generalized tonic–clonic seizures and thus is thought to be an experimental model of tonic–clonic epilepsy and of partial convulsions with or without secondary generalization in humans. The scPTZ test employs chemically induced myoclonic seizures and is proposed to identify the agents raising the seizure threshold. This test is related to human generalized absence seizures (Rogawski, 2006).

Considering the aforementioned facts, the profile of anticonvulsant activity of final compounds 3–24 was established in the MES and scPTZ tests, after intraperitoneal (i.p.) injection in mice at doses of 30, 100 and 300 mg/kg. An observation was carried out at two different time intervals—0.5 and 4 h. Furthermore, in addition to the primary anticonvulsant screening, the acute neurological toxicity (NT) was determined in mice by the rotarod test. The results of the preliminary pharmacological studies are summarized in Table 1.

Table 1.

Anticonvulsant and neurotoxicity screening after i.p. administration in mice (3–24)

No. R 1 R 2 X R 3 Intraperitoneal administration in micea clog P e
MESb scPTZc NTd
0.5 h 4 h 0.5 h 4 h 0.5 h 4 h
3 Cl H – – – – – – – – 3.15
4 Cl 2–Cl – – – – – – – – 3.71
5 Cl 4–Cl – – – – – – – – 3.71
6 Cl 2,3–Cl – – – – – – – – 4.26
7 Cl 2–F – – – – – – – – 3.31
8 Cl 4–F – – – – – – – – 3.31
9 Cl 3–CF3 – – – – – – – – 4.07
10 Cl – N graphic file with name 44_2015_1360_Figa_HTML.gif – – – – – – 1.72
11 Cl – N graphic file with name 44_2015_1360_Figb_HTML.gif – – – – 300 – 2.80
12 Cl – N –CH3 100 – – – – – 1.07
13 Cl – O – 100 300 – – 300 – 0.92
14 CF3 H – – – 100 – – 300Z 300 3.51
15 CF3 2–Cl – – – – – – – – 4.07
16 CF3 4–Cl – – – 100 – – – – 4.07
17 CF3 2,3–Cl – – – – – – – – 4.63
18 CF3 2–F – – – 100 – – – – 3.67
19 CF3 4–F – – 300 100 – – 300 – 3.67
20 CF3 3–CF3 – – – 100 – – – – 4.43
21 CF3 – N graphic file with name 44_2015_1360_Figc_HTML.gif – – – – 300 – 2.09
22 CF3 – N graphic file with name 44_2015_1360_Figd_HTML.gif 300 – – – 30033 – 3.17
23 CF3 – N –(CH2)2–OH 300 300 – – 300 – 0.92
24 CF3 – O – 100 – – – 100 – 1.28
Phenytoinf 30 30 – – 100 100
Open in a new tab

Response comments: Z respiratory depression, 33 tremors

aDoses of 30, 100 or 300 mg/kg were administered intraperitoneally. The data indicate the minimum dose effective or neurotoxic in half or more animals tested. A dash indicates the absence of anticonvulsant activity or neurotoxicity at the maximum dose administered

bMaximal electroshock test

cSubcutaneous pentylenetetrazole test

dNeurotoxicity screening using rotarod test

eclog P values calculated using a log P module of ChemDraw Ultra program, version 7.0.1 (Cambridge Soft Corporation, Cambridge, MA, USA)

fPhenytoin, reference antiepileptic drug, tested by use of ADD Program procedures in NIH/NINDS

The compounds tested showed protection exclusively in the MES seizures. Furthermore, in vivo data revealed that anticonvulsant activity was closely connected with the type of substituent at the 3-position of the anilide moiety. Except for N-(3-chlorophenyl)-2-(4-methylpiperazin-1-yl)acetamide (12)—effective in the MES test at 0.5 h (dose of 100 mg/kg) and N-(3-chlorophenyl)-2-morpholino-acetamide (13) which showed protection in both time points (100 mg/kg at 0.5 h, and 300 mg/kg at 4 h), all other 3-chloroanilides (3–11) were devoid of anticonvulsant activity. As it can be seen, considerably higher anticonvulsant protection was observed for 3-(trifluoromethyl)anilides (14–24). Among these derivatives, all compounds, except for those containing 4-(2-chlorophenyl)piperazine (15), 4-(2,3-dichlorophenyl)piperazine (17) and 4-pyrimidin-2-yl-piperazine (21), revealed protection in the MES test at dose of 100 mg/kg and/or 300 mg/kg in different pretreatment times. The highest anticonvulsant activity was observed for 19 which protected animals in both time intervals (300 mg/kg at 0.5 h, and 100 mg/kg at 4 h). Other active compounds with phenylpiperazine fragment as amine function (14, 16, 18, 20) revealed protection in the MES seizures only 4 h after i.p. administration that means delayed onset, however, long in duration anticonvulsant action. The anti-MES activity at dose of 100 mg/kg showed also morpholine derivative 24 (0.5 h). The differences in times points in which the anticonvulsant protection was observed for compounds containing morpholine (24) or phenylpiperazine moieties (14, 16, 18, 20) may result from the lipophilic properties of these molecules. As it is presented in Table 1, the more lipophilic molecules (higher clog P values)—14, 16, 18, 20 showed activity mainly at 4 h, whereas less lipophilic compound 24 was effective only at time point of 0.5 h. These observations may be connected with higher affinity of more lipophilic compounds to the peripheral tissues that causes slower distribution to the CNS. The further SAR analysis indicated that exchange of phenylpiperazine moiety into benzylpiperazine (22) or hydroxyethylpiperazine (23) decreased anticonvulsant activity. The screening data revealed that all active compounds showed weaker anti-MES protection than phenytoin that is still recognized as model AED active in MES test. Furthermore, the anticonvulsant protection was distinctly lower in comparison with respective succinimide analogs described in advance (Obniska et al., 2013). This observation confirms the role of pyrrolidine-2,5-dione ring as a pharmacophore crucial for anticonvulsant activity.

The pharmacological results obtained in the current studies proved that introduction of the fluorine atom or trifluoromethyl group was essential for anticonvulsant activity in this series of compounds. Furthermore, it is widely accepted that incorporation of fluorine into biologically active molecules provides analogs with increased metabolic stability due to strength of C–F bond and further reduction of cytochrome P450 oxidative metabolism. Moreover, the unique features of fluorine, such as relatively small size, combined with a very high electronegativity can specifically modulate the steric and electronic properties of the fluorinated derivatives and significantly affect biological activity. In addition, incorporation of fluorine residues into aromatic system leads to increased lipophilicity and better distribution to CNS (Kirk, 2006; Song et al., 2005; Ismail, 2002; Smart, 2001). It should be stressed here that beneficial influence of fluorine substitution on anticonvulsant activity was observed in a group of 2-azaspiro[4.4]nonane- and 2-azaspro[4.5]decane-1,3-diones described in advance (Obniska et al., 2006).

In the rotarod test (NT) for acute neurological toxicity, most of 3-chloro- as well as 3-(trifluoromethyl)anilides with electron-withdrawing substituents (Cl, F, CF3) at the phenylpiperazine fragment did not show neurotoxicity in the maximum dose administered (300 mg/kg). The other derivatives, namely 11, 13, 14, 19, 21–23 showed neurotoxicity at a dose of 300 mg/kg. At the same dose, mice showed respiratory depression after administration of 14 and revealed tremors after administration of 22. Only one compound 24 revealed neurotoxicity at a dose of 100 mg/kg.

According to the Anticonvulsant Screening Project dispositions, three compounds 13, 20 and 22 which showed protection in mice were selected and examined for their anticonvulsant activity (MES screen) and neurotoxicity after oral (p.o.) administration in rats at fixed dose 30 mg/kg. This screen discloses the time of onset, the approximate time of peak effect (TPE) and the duration of anticonvulsant activity or neurotoxicity. The results are shown in Table 2.

Table 2.

Anticonvulsant activity of selected compounds administrated orally in rats (MES screen)

No. Oral administration in ratsa
0.25 h 0.5 h 1 h 2 h 4 h
13 0/4 1/4 0/4 0/4 0/4
20 0/4 1/4 0/4 2/4 0/4
22 1/4 1/4 1/4 1/4 1/4
Phenytoinb 1/4 4/4 3/4 3/4 3/4
Open in a new tab

aDose of 30 mg/kg was administrated orally. The data indicate: number of rats protected/number of rats tested

bPhenytoin, reference antiepileptic drug, tested by use of ADD Program procedures in NIH/NINDS

Among derivatives tested, only 20 was active in 50 % of animals at time point 2 h. This compound was also active in 25 % of animals at 0.5 h. The other molecules revealed 25 % protection at 0.5 h (13) and in all five time intervals (25). All compounds given orally did not cause motor impairment in the rotarod screen (data not indicated in Table 2). The compounds tested showed lower activity than phenytoin which protected from 25 to 100 % of mice in different time intervals.

On the basis of the preliminary data in rats, compound 20 was chosen for quantification of the pharmacological parameters (ED50 and TD50) after p.o. application. The quantitative evaluation of the MES median effective dose (ED50) and toxic dose (TD50) was performed at previously estimated TPE—2 h. The results of the quantitative tests along with data for the standard AEDs—valproic acid, ethosuximide and phenytoin—are listed in Table 3.

Table 3.

Quantification data in rats after p.o. administration

No. TPE (h)a ED50 MESb (mg/kg) ED50 scPTZb (mg/kg) TD50 NTb (mg/kg) PI (TD50/ED50)c
20 2 52.30 (46.38–60.22) ND >500 >9.56 (MES)
Valproic acidd 1 485 (324–677) 646 (466–869) 784 (503–1176) 1.6 (MES) 1.2 (scPTZ)
Phenytoind 1 28.10 (20.7–35.2) >500 >100 >3.6 (MES)
Open in a new tab

ND not determined

aTime to peak effect

bResults are presented as mean ± SEM at 95 % confidence limit (MES maximal electroshock test, scPTZ subcutaneous pentylenetetrazole test, NT neurotoxicity, rotarod test)

cProtective index (TD50/ED50)

dReference antiepileptic drugs tested by use of ADD Program procedures in NIH/NINDS

The quantitative data showed that 20 had higher ED50 than phenytoin (MES test), however, was distinctly more potent than valproic acid in this seizure model. It should be emphasized that in both cases 20 revealed more favorable protective indexes in comparison with mentioned model AEDs. Furthermore, substance 20 was almost twice weaker in the MES test than model succinimides presented in Fig. 2. These results support strongly crucial role of succinimide ring for anticonvulsant activity.

In the next step of pharmacological investigations, four compounds 12, 19, 20 and 24 were chosen for the evaluation of anticonvulsant activity in the psychomotor 6-Hz test (Table 4). The selection was made randomly as a part of the search of molecules providing anti-6-Hz protection among chemically diversified compounds pursued in the NIH/NINDS. It should be noticed that 6-Hz screen has been validated as a model of therapy-resistant epilepsy (Barton et al., 2001). Furthermore, the 6-Hz stimulation is suggested to be capable for identifying anti-seizure agents with a novel spectrum of activity and unknown mechanism of anticonvulsant action. One example supporting this hypothesis is provided by levetiracetam, which has demonstrated efficacy in refractory human partial epilepsies. It was found to be inactive against classical MES and PTZ seizures even at high doses, whereas showed high effectiveness in the 6-Hz psychomotor seizure model of partial epilepsy (Rogawski, 2006). Thus, it is suggested that the 6-Hz model might be capable for identifying anti-seizure agents with a novel spectrum of activity and unknown mechanism of anticonvulsant action.

Table 4.

Anticonvulsant activity—i.p. psychomotor seizure test in mice (6-Hz)

No. Intraperitoneal injection into micea
0.25 h 0.5 h 1 h 2 h 4 h
12 3/4 3/4 0/4 0/4 0/4
19 0/4 0/4 0/4 0/4 1/4
20 1/4 0/4 0/4 1/4 1/4
24 4/4 2/4 3/4 0/4 0/4
Open in a new tab

Current 32 mA

aDose of 100 mg/kg was administrated intraperitoneally. The data indicate: number of mice protected/number of mice tested

The results obtained showed the most potent activity for morpholine derivative 24 which protected 100 % of mice at 0.25 h, 75 % of animals at 1 h and 50 % of animals at 0.5 h at a dose of 100 mg/kg after (i.p.). Compound 12 protected 75 % of animals at 0.25 and 0.5 h. The other compounds 19 and 20 were less active and protected 25 % of animals at 4 h (19) as well as at 0.25, 2 and 4 h (20). None of these compounds caused motor impairment during mentioned studies.

In vitro sodium channels radioligand binding studies

Intensive studies into the physiological and biochemical events taking place during epileptic seizures have provided insight into the molecular mechanisms by which these might be controlled. The fundamental role in establishing and regulating excitability of CNS neurons as well as suppression of seizures is ascribed to voltage-gated sodium channels (VGSCs) (Meldrum and Rogawski, 2007). Thus, the brain sodium channels are the molecular targets of numerous chemically diverse AEDs from which phenytoin and carbamazepine are the most representative (Rogawski and Löscher, 2004; Liu et al., 2003; Bialer et al., 2009). Using radioligand binding techniques, Catterall and associates have found an allosteric interaction between these drugs and the batrachotoxin (BTX) binding site of sodium channels from rat brain (Willow and Catterall, 1982; Catterall et al., 1981). Phenytoin and carbamazepine block the influx of sodium into rat brain synaptosomes elicited by BTX, which activates sodium channels (Willow et al., 1984). Electrophysiological studies of neuroblastoma cells demonstrate a frequency- and voltage-dependent blockade of sodium currents by both of these anticonvulsants (Willow et al., 1985; Matsuki et al., 1984). These findings suggest that blockade of sodium channel activity by these agents underlies their anticonvulsant actions. It should be stressed here that such mode of action is characteristic for compounds active in the MES seizure test in animals. Due to activity of reported compounds in the MES seizures, for the most active molecule 20, the binding assays for Na+ channel (site 2) were performed using the [3H] batrachotoxin as radioligand (Brown, 1986). Compound binding was calculated as a percent inhibition of the binding of a radioactively labeled ligand. The inhibition values for 20 were obtained in four concentrations, 1, 10, 100, and 500 μM. All experiments were performed in duplicate. The results are given in Table 5.

Table 5.

In vitro Na+ channel (site 2) binding assays

No. Concentration (μM) % Inhibition of control specific bindinga
20 1 4.2
10 7.5
100 10.8
500 46.7
Open in a new tab

aCompounds were each evaluated in synaptoneurosomal preparations from rat cerebral cortex as inhibitors of the specific binding of [3H]BTX to the voltage-sensitive sodium channel. Results showing an inhibition higher than 50 % are considered to represent significant effects of the test compounds; results showing an inhibition between 25 and 50 % are indicative of weak to moderate effects; results showing an inhibition lower than 25 % are not considered significant and mostly attributable to variability of the signal around the control level

As it can be seen, compound 20 was observed as a moderate binder to the neuronal voltage-sensitive sodium channel at the highest concentration—500 μM. This result may suggest different mechanism of anticonvulsant action than only influence on VGSCs.

Experimental

Chemistry

All the chemicals and solvents were purchased from Sigma-Aldrich (St. Louis, USA) and were used without further purification. Melting points (mp.) were determined in open capillaries on a Büchi 353 melting point apparatus (Büchi Labortechnik, Flawil, Switzerland) and are uncorrected. HPLC analyses were run on a HPLC Waters® 2695 Separation Module equipped with photodiode array detector (Waters® 2998). A Chromolith RP–18 SpeedROD column (4.6 × 50 mm) was used. Conditions applied were as follows: eluent A (water/0.1 % TFA), eluent B (acetonitrile/0.1 % TFA), flow rate 5 ml/min, gradient of 0–100 % B over 3 min were used, and injection volume was 10 µl. Standard solutions (1 mg/ml) of each compound were prepared in analytical grade acetonitrile and analyzed at wavelengths 214 and 254 nm. Retention times (R t) are given in minutes. Elemental analysis for C, H, and N was carried out by a micro method using the elemental Vario EI III Elemental analyzer (Hanau, Germany). The results of elemental analyses were within ±0.4 % of the theoretical values. 1H NMR,13C NMR and 19F NMR spectra were obtained in a Varian Mercury spectrometer (Varian Inc., Palo Alto, CA, USA), in CDCl3 operating at 300 MHz (1H NMR), 75 MHz (13C NMR) and 282 MHz (19F NMR). Chemical shifts are reported in δ values (ppm) relative to TMS δ = 0 (1H), as internal standard. The J values are expressed in Hertz (Hz). Signal multiplicities are represented by the following abbreviations: s (singlet), brs (broad singlet), d (doublet), ddd (double double doublet), t (triplet) and m (multiplet). The mass spectra were obtained on Waters ACQUITY™ TQD system with the TQ detector (Waters, Milford, USA). The ACQUITY UPLC BEH C18, 1.7 µm, 2.1 × 50 mm column was used (Waters, Milford, USA).

General procedure for preparation of intermediates 1 and 2

A total of 0.05 mol of the 3-chloroaniline or 3-trifluoromethylaniline was dissolved in 30 ml of DCM and mixed with 5 ml 2 % aqueous solution of sodium hydroxide. Then, 0.05 mol of 2-chloroacetyl chloride dissolved in DCM (10 ml) was added dropwise over an hour. During that time, the reaction mixture was cooled with ice. After the acylating agent was added, stirring was continued for 2 h. Subsequently, the reaction mixture was extracted with saturated potassium bisulfate solution, water and brine. The organic layer was dried over the anhydrous sodium sulfate an distilled of on a rotary evaporator to obtain white crystalline powders.

2-Chloro-N-(3-chlorophenyl)acetamide (1)

White powdery crystals; mp 84–85 °C; HPLC: R t = 1.089 min; 1H NMR (CDCl3): δ 4.21 (s, 2H, –CH2–), 7.41–7.50 (m, 2H, ArH), 7.58–7.78 (d, 1H, ArH, J = 7.70 Hz), 7.85 (s, 1H, ArH), 8.31 (brs, 1H, NH); 13C NMR (75 MHz, CDCl3): δ 43.3 (–CH2–), 115.6, 119.2, 124.2, 126.7, 131.6, 139.2 (6Caromatic), 168.8 (–CO–). ESI–MS: 204.1 (C8H7Cl2NO [M+H]+). Anal. Calcd for C8H7Cl2NO (204.05): C, 47.09; H, 3.46; N, 6.85. Found: C, 47.19; H, 3.55, N, 6.70.

2-Chloro-N-[3-(trifluoromethyl)phenyl]acetamide (2)

White powdery crystals; mp 72–73 °C; HPLC: R t = 1.201 min; 1H NMR (300 MHz, CDCl3): δ 4.21 (s, 2H, –CH2–), 7.42–7.52 (m, 2H, ArH), 7.57–7.78 (m, 1H, ArH, J = 7.70 Hz), 7.85 (s, 1H, ArH), 8.33 (brs, 1H, NH); 13C NMR (75 MHz, CDCl3): δ 45.6 (–CH2–), 107.2 (–CF3), 117.1, 118.6, 120.5, 123.3, 126.4, 130.8, 135.6 (6Caromatic), 168.8 (–CO–). ESI–MS: 238.10 (C9H7ClF3NO [M+H]+). Anal. Calcd for C9H7ClF3NO (237.61): C, 45.49; H, 2.98; N, 5.89. Found: C, 45.55; H, 3.15, N, 5.88.

General procedure for the synthesis of final compounds 3–24

A total of 0.002 mol of intermediate 1 or 2 and equimolar amount of corresponding secondary amine were dissolved in 10 ml of dry acetone. 0.006 mol of dry potassium carbonate and catalytic amount of potassium iodide were added, and the reaction mixture was stirred for about 24 h at a temperature of 60 °C (HPLC control). After this time, inorganic ingredients were filtered off and acetone was distilled off on a rotary evaporator. The crude products were obtained as colored oils. Compounds 3–22 and 24 were purified by column chromatography on Silica gel 60 (Merck, Darmstadt, Germany) using a dichloromethane–methanol (9: 0.7 v/v) mixture as a solvent system. Due to oily form, compounds 3–13, 15, 18–21, 23 and 24 were converted into hydrochloride salts in anhydrous ethanol saturated with HCl gas. They were crystallized from anhydrous ethanol.

N-(3-chlorophenyl)-2-(4-phenylpiperazin-1-yl)acetamide monohydrochloride (3)

White powdery crystals; mp. 199–201 °C; HPLC: R t = 1.357 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.06–3.93 (m, 8H, piperazine), 4.33 (s, 2H, –CH2–), 6.81–6.89 (m, 1H, ArH), 6.96–7.05 (m, 1H, ArH), 7.12–7.29 (m, 4H, ArH), 7.32–7.41 (m, 1H, ArH), 7.53–7.60 (m, 1H, ArH), 7.76–7.86 (m, 1H, ArH), 10.86 (brs, 1H, NH), 11.55 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 51.3 (–CH2–), 51.9 (–CH2–), 52.5 (–CH2–), 53.3 (–CH2–), 54.1 (–CH2–), 111.7, 117.0, 118.5, 123.6, 130.2, 130.9, 135.4, 140.6, 146.3 (12Caromatic), 172.1 (–CO–). ESI–MS: 330.4 (C18H20ClN3O [M+H]+). Anal. Calcd for C18H21Cl2N3O (366.28): C, 59.02; H, 5.78; N, 11.47. Found: C, 59.12; H, 5.90, N, 11.50.

N-(3-chlorophenyl)-2-[4-(2-chlorophenyl)piperazin-1-yl]acetamide monohydrochloride (4)

White powdery crystals; mp. 238–240 °C; HPLC: R t = 1.456 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.09–3.50 (m, 8H, piperazine), 4.33 (s, 2H, –CH2–), 7.06–7.22 (m, 3H, ArH), 7.29–7.45 (m, 3H, ArH), 7.56 (ddd, 1H, ArH, J = 8.23, 1.92, 0.91 Hz), 7.82–7.88 (m, 1H, ArH), 10.87 (s, 1H, NH), 11.43 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 51.8 (–CH2–), 52.3 (–CH2–), 53.1 (–CH2–), 54.3 (–CH2–), 54.9 (–CH2–), 110.6, 116.8, 117.5, 118.3, 118.8, 124.5, 126.5, 130.3, 131.1, 136.8, 140.1, 144.2 (12Caromatic), 173.2 (–CO–). ESI–MS: 365.2 (C18H19Cl2N3O [M+H]+). Anal. Calcd for C18H20N3OCl3 (400.73): C, 53.95; H, 5.03; N, 10.49. Found: C, 54.03; H, 5.12; N, 10.55.

N-(3-chlorophenyl)-2-[4-(4-chlorophenyl)piperazin-1-yl]acetamide monohydrochloride (5)

White powdery crystals; mp. 217–219 °C; HPLC: R t = 0.747 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.06–4.12 (m, 8H, piperazine), 4.30 (s, 2H, –CH2–), 6.96–7.04 (m, 2H, ArH), 7.15–7.20 (m, 1H, ArH), 7.24–7.31 (m, 2H, ArH), 7.37 (t, 1H, ArH, J = 8.11 Hz), 7.54 (d, 1H, ArH, J = 8.46 Hz), 7.83–7.84 (m, 1H, ArH), 10.71 (s, 1H, NH), 11.37 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 52.0 (–CH2–), 52.8 (–CH2–), 53.2 (–CH2–), 54.1 (–CH2–), 54.8 (–CH2–), 112.6, 114.5, 118.5, 119.3, 124.8, 126.6, 129.5, 135.7, 141.5, 146.4 (12Caromatic), 174.1 (–CO–). ESI–MS: 365.2 (C18H19Cl2N3O [M+H]+). Anal. Calcd for C18H20Cl3N3O (400.73): C, 53.95; H, 5.03; N, 10.49. Found: C, 53.98; H, 5.09; N, 10.53.

N-(3-chlorophenyl)-2-[4-(2,3-dichlorophenyl)piperazin-1-yl]acetamide monohydrochloride (6)

White powdery crystals; mp. 241–242 °C; HPLC: R t = 1.601 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.14–3.78 (m, 8H, piperazine), 4.31 (s, 2H, –CH2–), 7.14–7.25 (m, 2H, ArH), 7.30–7.42 (m, 3H, ArH), 7.51–7.57 (m, 1H, ArH), 7.82–7.86 (m, 1H, ArH), 10.79 (brs, 1H, NH), 11.32 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 52.2 (–CH2–), 53.3 (–CH2–), 53.9 (–CH2–), 54.5 (–CH2–), 55.6 (–CH2–), 116.6, 117.1, 117.5, 118.7, 119.8, 124.7, 126.6, 129.3, 130.1, 136.5, 140.8, 147.1 (12Caromatic), 174.6 (–CO–). ESI–MS: 399.3 (C18H18Cl3N3O [M+H]+). Anal. Calcd for C18H19Cl4N3O (435.17): C, 49.68; H, 4.40; N, 9.66. Found: C, 49.75; H, 4.48; N, 9.74.

N-(3-chlorophenyl)-2-[4-(2-fluorophenyl)piperazin-1-yl]acetamide monohydrochloride (7)

White powdery crystals; mp. 224–225 °C; HPLC: R t = 1.393 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.02–3.79 (m, 8H, piperazine), 4.32 (s, 2H, –CH2–), 6.98–7.21 (m, 5H, ArH), 7.33–7.42 (m, 1H, ArH), 7.56 (ddd, 1H, ArH, J = 8.23, 2.03, 1.03 Hz), 7.85 (t, 1H, ArH, J = 1.97 Hz), 10.84 (brs, 1H, NH), 11.45 (brs, 1H, +NH); 13C NMR (75 MHz, CDCl3): δ 50.8 (–CH2–), 51.9 (–CH2–), 53.2 (–CH2–), 54.4 (–CH2–), 55.8 (–CH2–), 114.2, 115.3, 116.5, 117.0, 117.8, 122.9, 125.4, 129.1, 129.6, 134.4, 138.5, 143.2 (12Caromatic), 171.9 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –122.92–(–122.83) (m, 1F). ESI–MS: 348.8 (C18H19ClFN3O [M+H]+). Anal. Calcd for C18H20Cl2FN3O (384.28): C, 56.26; H, 5.25; N, 10.93. Found: C, 56.30; H, 5.32; N, 11.04.

N-(3-chlorophenyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]acetamide monohydrochloride (8)

White powdery crystals; mp. 214–216 °C; HPLC: R t = 1.392 min; 1H NMR (300 MHz, DMSO–d 6): δ 2.95–3.89 (m, 8H, piperazine), 4.32 (s, 2H, –CH2–), 6.96–7.19 (m, 4H, ArH), 7.36 (t, 2H, ArH, J = 8.11 Hz), 7.54–7.60 (m, 1H, ArH), 7.84–7.87 (m, 1H, ArH), 10.86 (brs, 1H, NH), 11.55 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 52.5 (–CH2–), 53.5 (–CH2–), 54.6 (–CH2–), 55.5 (–CH2–), 56.3 (–CH2–), 115.2, 116.4, 117.2, 117.9, 123.9, 125.8, 129.0, 134.6, 140.1, 145.1 (12Caromatic), 173.2 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –123.98 (s, 1F). ESI–MS: 348.7 (C18H19ClFN3O [M+H]+). Anal. Calcd for C18H20Cl2FN3O (384.28): C, 56.26; H, 5.25; N, 10.93. Found: C, 56.35; H, 5.34; N, 10.99.

N-(3-chlorophenyl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetamide monohydrochloride (9)

White powdery crystals; mp. 199–200 °C; HPLC: R t = 1.602 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.15–3.49 (m, 4H, piperazine), 3.57–3.70 (m, 2H, piperazine), 3.87–4.01 (m, 2H, piperazine), 4.33 (s, 2H, –CH2–), 7.10–7.18 (m, 2H, ArH), 7.21–7.30 (m, 2H, ArH), 7.32–7.49 (m, 2H, ArH), 7.54–7.60 (m, 1H, ArH), 7.85 (t, 1H, ArH, J = 2.00 Hz), 10.95 (brs, 1H, NH), 11.56 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 49.8 (–CH2–), 51.2 (–CH2–), 52.8 (–CH2–), 54.5 (–CH2–), 55.7 (–CH2–), 116.6, 118.0, 118.5, 119.1, 119.9, 121.2, 123.9, 125.6, 129.1, 131.2, 137.4, 139.9, 141.8 (–CF3, 12Caromatic), 170.5 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –61.07 (s, 3F). ESI–MS: 398.4 (C19H19ClF3N3O [M+H]+). Anal. Calcd for C19H20Cl2F3N3O (434.28): C, 52.55; H, 4.64; N, 9.68. Found: C, 52.68; H, 4.77; N, 9.80.

N-(3-chlorophenyl)-2-(4-pyrimidin-2-ylpiperazin-1-yl)acetamide monohydrochloride (10)

White powdery crystals; mp. 248–249 °C; HPLC: R t = 1.138 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.11–3.74 (m, 8H, piperazine), 4.28 (s, 2H, –CH2–), 6.76 (t, 1H, ArH, J = 4.79 Hz), 7.16 (ddd, 1H, ArH, J = 8.02, 2.12, 1.01 Hz), 7.36 (t, 1H, ArH, J = 8.09 Hz), 7.52–7.58 (m, 1H, ArH), 7.84 (t, 1H, ArH, J = 1.97 Hz), 8.40–8.48 (m, 2H, ArH), 10.91 (brs, 1H, NH), 11.50 (brs, 1H, HCl); 13C NMR (75 MHz, DMSO–d 6): δ 50.2 (–CH2–), 52.1 (–CH2–), 54.1 (–CH2–), 55.2 (–CH2–), 56.1 (–CH2–), 115.2, 117.9, 120.1, 123.3, 129.4, 133.1, 137.8, 158.5, 164.9 (10Caromatic), 170.8 (–CO–). ESI–MS: 332.7 (C16H18ClN5O [M+H]+). Anal. Calcd for C16H19Cl2N5O (368.26): C, 52.18; H, 5.20; N, 19.02. Found: C, 52.23; H, 5.29; N, 19.08.

2-(4-Benzylpiperazin-1-yl)-N-(3-chlorophenyl)acetamide dihydrochloride (11)

White powdery crystals; mp. 245–247 °C; HPLC: R t = 1.254 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.21–3.78 (m, 8H, piperazine), 4.15 (s, 2H, –CH2–), 4.40 (s, 2H, –CH2–), 7.15 (ddd, 1H, ArH, J = 7.95, 2.05, 1.03 Hz), 7.35 (t, 1H, ArH, J = 8.08 Hz), 7.41–7.48 (m, 3H, ArH), 7.48–7.55 (m, 1H, ArH), 7.60–7.70 (m, 2H, ArH), 7.82 (t, 1H, ArH, J = 2.05 Hz), 9.94 (s, 1H, NH), 11.17 (brs, 1H, +NH), 12.11 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 50.3 (–CH2–), 51.5 (–CH2–), 52.7 (–CH2–), 53.8 (–CH2–), 54.4 (–CH2–), 65.7 (–CH2–, benzyl), 115.2, 116.9, 118.2, 124.8, 129.2, 130.4, 134.8, 136.5, 139.4 (12Caromatic), 174.6 (–CO–). ESI–MS: 344.8 (C19H22ClN3O [M+H]+). Anal. Calcd for C19H24Cl3N3O (416.77): C, 54.75; H, 5.80; N, 10.08. Found: C, 54.90; H, 5.94; N, 10.11.

N-(3-chlorophenyl)-2-(4-methylpiperazin-1-yl)acetamide dihydrochloride (12)

White powdery crystals; mp. 237–238 °C; HPLC: R t = 0.958 min; 1H NMR (300 MHz, DMSO–d 6) δ 2.80 (s, 3H, CH3), 3.25–3.79 (m, 8H, piperazine), 4.17 (s, 2H, –CH2–), 7.15 (ddd, 1H, ArH, J = 8.01, 2.12, 0.90 Hz), 7.35 (t, 1H, ArH, J = 8.09 Hz), 7.53 (ddd, 1H, ArH, J = 8.22, 2.04, 1.03 Hz), 7.83 (t, 1H, ArH, J = 1.92 Hz), 10.91 (brs, 1H, NH), 11.22 (brs, 1H, +NH), 11.89 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 32.8 (–CH3), 49.6 (–CH2–), 50.6 (–CH2–), 51.7 (–CH2–), 52.6 (–CH2–), 53.4 (–CH2–), 118.0, 120.5, 123.2, 125.6, 129.8, 137.9 (6Caromatic), 169.8 (–CO–). ESI–MS: 268.7 (C13H18ClN3O [M+H]+). Anal. Calcd for C13H20Cl3N3O (340.68): C, 45.83; H, 5.92; N, 12.33. Found: C, 45.88; H, 5.99; N, 12.41.

N-(3-chlorophenyl)-2-morpholino-acetamide monohydrochloride (13)

White powdery crystals; mp. 189–190 °C; HPLC: R t = 1.067 min; 1H NMR (300 MHz, DMSO–d 6): δ 1.59–1.88 (m, 4H, morpholine), 2.96–3.56 (m, 4H, morpholine), 4.15 (s, 2H, –CH2–), 7.13–7.19 (m, 1H, ArH), 7.37 (t, 1H, ArH, J = 8.08 Hz), 7.51–7.57 (m, 1H, ArH), 7.82–7.86 (m, 1H, ArH), 10.05 (brs, 1H, NH), 11.41 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 51.8 (–CH2–), 52.6 (–CH2–), 53.2 (–CH2–), 67.8 (–CH2–), 68.6 (–CH2–), 117.8, 120.3, 122.9, 125.8, 128.4, 138.1 (6Caromatic), 171.5 (–CO–). ESI–MS: 255.7 (C12H15Cl N2O2 [M+H]+). Anal. Calcd for C12H16 Cl2N2O2 (291.17): C, 49.50; H, 5.54; N, 9.62. Found: C, 49.54; H, 5.61; N, 9.68.

2-(4-Phenylpiperazin-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide (14)

White powdery crystals; mp. 152–153 °C; HPLC: R t = 1.204 min; 1H NMR (300 MHz, CDCl3): δ 2.81 (t, 4H, piperazine, J = 5.0 Hz), 3.23 (s, 2H, –CH2–), 3.29 (t, 4H, piperazine, J = 5.0 Hz), 6.87–6.97 (m, 3H, ArH), 7.25–7.32 (m, 2H, ArH), 7.37 (d, 1H, ArH, J = 7.44 Hz), 7.46 (t, 1H, ArH, J = 8.6 Hz), 7.82 (s, 2H, ArH), 9.27 (s, 1H, NH); 13C NMR (75 MHz, CDCl3): δ 52.5 (–CH2–), 53.2 (–CH2–), 53.8 (–CH2–), 54.7 (–CH2–), 55.3 (–CH2–), 109.7, 116.1, 117.5, 118.3, 123.5, 128.2, 129.7, 136.4, 139.9, 147.4 (–CF3, 12Caromatic), 175.3 (–CO–); 19F NMR (282 MHz, CDCl3): δ –62.74 (s, 3F). ESI–MS: 364.0 (C19H20F3N3O [M+H]+). Anal. Calcd for C19H20F3N3O (363.38): C, 62.80; H, 5.55; N, 11.56. Found: C, 62.86; H, 5.62; N, 11.63.

2-[4-(2-Chlorophenyl)piperazin-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide monohydrochloride (15)

White powdery crystals; mp. 239–241 °C; HPLC: R t = 1.298 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.14–3.65 (m, 8H, piperazine), 4.33 (s, 2H, –CH2–), 7.10 (t, 1H, ArH, J = 7.59 Hz), 7.25 (d, 1H, ArH, J = 7.95 Hz), 7.33 (t, 1H, ArH, J = 7,71 Hz), 7.45 (t, 2H, ArH, J = 8.46 Hz), 7.62 (t, 1H, ArH, J = 7.95 Hz), 7.85 (d, 1H, ArH, J = 8.46 Hz), 8.14 (s, 1H, ArH), 10.78 (brs, 1H, NH), 11.47 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 52.6 (–CH2–), 52.9 (–CH2–), 53.5 (–CH2–), 54.3 (–CH2–), 54.9 (–CH2–), 109.8, 116.4, 117.6, 118.5, 119.8, 120.4, 123.2, 126.0, 130.6, 131.2, 135.7, 139.8, 143.9 (–CF3, 12Caromatic), 175.1 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –61.43 (s, 3F). ESI–MS: 397.8 (C19H19ClF3N3O [M+H]+). Anal. Calcd for C19H20Cl2F3N3O (434.28): C, 52.55; H, 4.64; N, 9.68. Found: C, 52.61; H, 4.79; N, 9.79.

2-[4-(4-Chlorophenyl)piperazin-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide (16)

White powdery crystals; mp. 170–171 °C; HPLC: R t = 1.365 min; 1H NMR (300 MHz, CDCl3): δ 2.79 (t, 4H, piperazine, J = 5.00 Hz), 3.23 (s, 2H, –CH2–), 3.25 (t, 4H, piperazine, J = 4.87 Hz) 6.83–6.89 (m, 2H, ArH), 7.20–7.26 (m, 2H, ArH), 7.37 (d, 1H, ArH, J = 7.44 Hz), 7.46 (t, 1H, ArH, J = 8.6 Hz), 7.81 (s, 2H, ArH), 9.23 (s, 1H, NH); 13C NMR (75 MHz, CDCl3): δ 51.5 (–CH2–), 52.5 (–CH2–), 53.5 (–CH2–), 54.0 (–CH2–), 55.3 (–CH2–), 111.3, 116.5, 117.9, 118.6, 119.8, 124.5, 126.8, 129.9, 136.8, 141.7, 144.4 (–CF3, 12Caromatic), 173.5 (–CO–); 19F NMR (282 MHz, CDCl3): δ –62.74 (s, 3F). ESI–MS: 398.3 (C19H19ClF3N3O [M+H]+). Anal. Calcd for C19H19ClF3N3O (397.82): C, 57.36; H, 4.81; N, 10.56. Found: C, 57.49; H, 4.89; N, 10.63.

2-[4-(2,3-Dichlorophenyl)piperazin-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide (17)

White powdery crystals; mp. 174–175 °C; HPLC: R t = 1.434 min; 1H NMR (300 MHz, CDCl3): δ 2.84 (t, 4H, piperazine, J = 4.74 Hz), 3.15 (t, 4H, piperazine, J = 4.48 Hz), 3.23 (s, 2H, –CH2–), 6.98–7.02 (m, 1H, ArH), 7.14–7.21 (m, 2H, ArH), 7.37 (d, 1H, ArH, J = 7.69 Hz), 7.46 (t, 1H, ArH, J = 7.95 Hz), 7.79 (s, 1H, ArH), 7.87 (d, 1H, ArH, J = 8.2 Hz), 9.28 (brs, 1H, NH); 13C NMR (75 MHz, CDCl3): δ 53.2 (–CH2–), 54.0 (–CH2–), 54.8 (–CH2–), 55.5 (–CH2–), 56.7 (–CH2–), 115.8, 117.0, 117.8, 118.5, 119.5, 120.6, 124.3, 126.2, 129.5, 131.8, 137.5, 141.1, 146.2 (–CF3, 12Caromatic), 175.8 (–CO–); 19F NMR (282 MHz, CDCl3): δ –62.70 (s, 3F). ESI–MS: 432.1 (C19H18Cl2F3N3O [M+H]+). Anal. Calcd for C19H18Cl2F3N3O (432.27): C, 52.79; H, 4.20; N, 9.72. Found: C, 52.90; H, 4.28; N, 9.83.

2-[4-(2-Fluorophenyl)piperazin-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide monohydrochloride (18)

White powdery crystals; mp. 228–231 °C; HPLC: R t = 1.247 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.21–3.63 (m, 8H, piperazine), 4.30 (s, 2H, –CH2–), 7.00–7.20 (m, 5H, ArH), 7.48 (d, 1H, ArH, J = 7.69 Hz), 7.61 (t, 1H, ArH, J = 8.07 Hz), 7.83 (d, 1H, ArH, J = 8.46 Hz), 10.61 (brs, 1H, NH), 11,35 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 51.7 (–CH2–), 52.9 (–CH2–), 53.5 (–CH2–), 54.4 (–CH2–), 55.5 (–CH2–), 111.0, 114.2, 115.9, 116.3, 117.0, 119.8, 121.7, 125.1, 128.8, 129.9, 133.8, 140.5, 147.1 (–CF3, 12Caromatic), 176.6 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –122.93–(–122.84) (m, 1F), –61.43 (s, 3F). ESI–MS: 381.9 (C19H19F4N3O [M+H]+). Anal. Calcd for C19H20ClF4N3O (417.82): C, 54.62; H, 4.82; N. 10.06. Found: C, 54.67; H, 4.92; N, 10.15.

2-[4-(4-Fluorophenyl)piperazin-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide monohydrochloride (19)

White powdery crystals; mp. 204–206 °C; HPLC: R t = 1.219 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.13–3.69 (m, 8H, piperazine), 4.32 (s, 2H, –CH2–), 6.98–7.12 (m, 4H, ArH), 7.48 (d, 1H, ArH, J = 7.69 Hz), 7.60 (t, 1H, ArH, J = 7.95 Hz), 7.84 (d, 1H, ArH, J = 8.46 Hz), 8.14 (s, 1H, ArH), 10,72 (brs, 1H, NH), 11,48 (s, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 52.1 (–CH2–), 53.0 (–CH2–), 53.9 (–CH2–), 54.5 (–CH2–), 55.3 (–CH2–), 112.2, 115.8, 117.5, 118.6, 120.7, 124.4, 125.9, 129.2, 135.7, 141.9, 146.8 (–CF3, 12Caromatic), 175.3 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –124.07 (s, 1F), –61.42 (s, 3F). ESI–MS: 381.8 (C19H19F4N3O [M+H]+). Anal. Calcd for C19H20ClF4N3O (417.82): C, 54.62; H, 4.82; N, 10.06. Found: C, 54.67;, 4.93; N, 10.13.

N-[3-(Trifluoromethyl)phenyl]-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetamide monohydrochloride (20)

White powdery crystals; mp. 189–190 °C; HPLC: R t = 1.437 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.13–3.69 (m, 8H, piperazine), 4.33 (s, 2H, –CH2–), 7.10–7.18 (m, 2H, ArH), 7.21–7.30 (m, 2H, ArH), 7.32–7.49 (m, 2H, ArH), 7.54–7.60 (m, 1H, ArH), 7.85 (t, 1H, ArH, J = 2.00 Hz), 10.61 (brs, 1H, NH), 11.46 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): 52.2 (–CH2–), 52.9 (–CH2–), 53.8 (–CH2–), 55.7 (–CH2–), 56.8 (–CH2–), 115.2, 117.8, 118.6, 119.2, 119.9, 120.5, 121.6, 124.0, 126.3, 129.8, 131.7, 139.4, 142.2, 148.8 (–CF3, –CF3, 12Caromatic), 177.2 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –61.41 (s, 3F), –61.35 (s, 3F). ESI–MS: 431.4 (C20H19F6N3O [M+H]+). Anal. Calcd for C20H20ClF6N3O (467.84): C, 51.35; H, 4.31; N, 8.98. Found: C, 51.49; H, 4.44; N, 9.04.

2-(4-Pyrimidin-2-ylpiperazin-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide monohydrochloride (21)

White powdery crystals; mp. 149–150 °C; HPLC: R t = 1.147 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.14–3.80 (m, 8H, piperazine), 4.26 (s, 2H, –CH2–), 6.75 (t, 1H, ArH, J = 4.87 Hz), 7.48 (d, 1H, ArH, J = 7.18 Hz), 7.61 (t, 1H, ArH, J = 8.08 Hz), 7.78–7.82 (m, 1H, ArH), 8.12 (s, 1H, ArH), 8.44 (d, 2H, ArH, J = 4.88 Hz), 10.59 (s, 1H, NH), 11.26 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 51.4 (–CH2–), 52.5 (–CH2–), 53.3 (–CH2–), 54.1 (–CH2–), 55.2 (–CH2–), 113.1, 118.8, 120.1, 121.3, 124.5, 129.9, 132.6, 139.8, 157.9, 167.8 (–CF3, 10Caromatic), 174.2 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –61.42 (s, 3F). ESI–MS: 366.0 (C17H18F3N5O [M+H]+). Anal. Calcd for C17H19ClF3N5O (401.81): C, 50.82; H, 4.77; N, 17.43. Found: C, 50.97; H, 4.82; N, 17.55.

2-(4-Benzylpiperazin-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide (22)

White powdery crystals; mp. 115–116 °C; HPLC: R t = 1.147 min; 1H NMR (300 MHz, CDCl3): δ 2.55–2.67 (m, 8H, piperazine), 3.15 (s, 2H, –CH2–), 3.56 (s, 2H, –CH2–), 7.24–7.37 (m, 6H, ArH), 7.45 (t, 1H, ArH, J = 7.95 Hz), 7.79–7.83 (m, 2H, ArH), 9.29 (s, 1H, NH); 13C NMR (75 MHz, CDCl3): δ 49.2 (–CH2–), 50.1 (–CH2–), 51.2 (–CH2–), 52.3 (–CH2–), 53.5 (–CH2–), 65.8 (–CH2–), 114.8, 117.5, 118.6, 120.2, 125.3, 128.9, 130.9, 133.7, 135.8, 138.3 (–CF3, 12Caromatic), 175.5 (–CO–); 19F NMR (282 MHz, CDCl3): δ –62.70 (s, 3F). ESI–MS: 378.4 (C20H22F3N3O [M+H]+). Anal. Calcd for C20H22F3N3O (377.40): C, 63.65; H, 5.88; N, 11.13. Found: C, 63.73; H, 5.96; N, 11.28.

2-[4-(2-Hydroxyethyl)piperazin-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide dihydrochloride (23)

White powdery crystals; mp. 210–212 °C; HPLC: R t = 0.841 min; 1H NMR (300 MHz, DMSO–d 6): δ 3.23–3.94 (m, 15H; 8H: piperazine, 4H: –C2H4–, 2H: –CH2–, 1H: –OH), 7.55 (d, 2H, ArH, J = 7.42 Hz), 7.58 (t, 1H, ArH, J = 7.95 Hz), 7.84 (d, 1H, ArH, J = 8,2 Hz), 9.75 (brs, 1H, NH), 10.97 (brs, 1H, +NH), 11.89 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 47.5 (–CH2–), 48.6 (–CH2–), 49.9 (–CH2–), 51.1 (–CH2–), 52.4 (–CH2–), 63.4 (–CH2–), 118.7, 119.6, 120.8, 123.1, 125.8, 131.6, 138.8 (–CF3, 6Caromatic), 170.9 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –61.41 (s, 3F). ESI–MS: 332.2 (C15H20F3N3O2 [M+H]+). Anal. Calcd for C15H22Cl2F3N3O2 (404.26): C, 44.57; H, 5.49; N, 10.39. Found: C, 44.65; H, 5.57; N, 10.48.

2-Morpholino-N-[3-(trifluoromethyl)phenyl]acetamide monohydrochloride (24)

White powdery crystals; mp. 185–186 °C; HPLC: R t = 0.985 min; 1H NMR (300 MHz, DMSO–d 6): δ 1.65–1.77 (m, 4H, morpholine), 3.14–3.48 (m, 4H, morpholine), 4.16 (s, 2H, –CH2–), 7.47 (d, 1H, ArH, J = 7.70 Hz), 7.59 (t, 1H, ArH, J = 7.94 Hz), 7.83 (d, 1H, ArH, J = 8.20 Hz), 8.12 (s, 1H, ArH), 9.96 (brs, 1H, NH), 11.42 (brs, 1H, +NH); 13C NMR (75 MHz, DMSO–d 6): δ 50.3 (–CH2–), 51.5 (–CH2–), 52.2 (–CH2–), 67.5 (–CH2–), 67.6 (–CH2–), 117.6, 119.2, 121.0, 123.3, 125.8, 133.4, 137.9 (–CF3, 6Caromatic), 172.1 (–CO–); 19F NMR (282 MHz, DMSO–d 6): δ –61.44 (s, 3F). ESI–MS: 289.2 (C13H15F3N2O2 [M+H]+). Anal. Calcd for C13H16ClF3N2O2 (324.72): C, 48.08; H, 4.97; N, 8.63. Found: C, 48.20; H, 5.02; N, 8.75.

Pharmacology

In vivo studies

Compounds 3–24 were pharmacologically preevaluated within the Antiepileptic Drug Development (ADD) Program in Epilepsy Branch, Neurological Disorders Program, National Institute of the Neurological and Communicative Disorders and Stroke (NIH/NINDS), Rockville, MD, USA, by using procedures described elsewhere (Krall et al., 1978; Kupferberg, 1989).

Phase I of the in vivo studies involved three tests: MES, scPTZ and rotarod test for NT. Male albino mice (CF#1 strain, weighing 18–25 g) and male albino rats (Sprague–Dawley) were used as experimental animals. The animals were housed in metabolic cages and allowed free access to food and water. The compounds were injected intraperitoneally to mice as a suspension in 0.5 % methylcellulose/water mixture at a dose level 30, 100 or 300 mg/kg with anticonvulsant activity and neurotoxicity assessment at 0.5 and 4 h after administration. Promising derivatives from phase I underwent phase VIa in which they were administrated orally into rats at a fixed dose of 30 mg/kg for both MES and the rotarod toxicity determination at five pretreatment times: 0.25, 0.5, 1, 2, 4 h. Groups of eight mice or four rats are employed.

Maximal electroshock seizure test (MES)

In the MES screen, an electrical stimulus of 0.2 s in duration (50 mA in mice and 150 mA in rats) is delivered via corneal electrodes primed with an electrolyte solution containing an anesthetic agent. The endpoint is the tonic extension of the hind limbs. In the control groups, the procedures cause immediate hind limb tonic extension. Mice not displaying hind limb tonic extension are considered to be protected from seizures.

Subcutaneous pentylenetetrazole seizure test (scPTZ)

The scPTZ test utilizes a dose of pentylenetetrazole (85 mg/kg in mice) that produces clonic seizures lasting for a period of at least 5 s in 97 % (CD97) of animals tested. PTZ is administered 0.5 and 4 h after injections of tested compounds, and observation is carried out for 30 min. In the control groups, the first episode of clonic convulsions is observed between 6 and 15 min of observation. The absence of clonic convulsions in the observed time period of 0.5 and 4 h is interpreted as the compound’s ability to protect against PTZ-induced seizures.

Neurotoxicity screening

The neurological toxicity test (NT) induced by a compound was detected in mice or rats using standardized rotarod test (Dunham and Miya, 1957). Untreated control mice or rats, when placed on the rod, can maintained their equilibrium for a prolonged time period. The acute motor impairment can be demonstrated by the inability of the animal to maintain equilibrium for 1 min in each of three successive trials.

The psychomotor 6-Hz model

The 6-Hz model is an alternative electroshock paradigm that uses low-frequency (6 Hz), long-duration (3 s) electrical stimulation. Corneal stimulation (0.2 ms duration monopolar rectangular pulses at 6-Hz for 3 s) was delivered by a constant-current device. During the stimulation, mice were manually restrained and released into the observation cage immediately after the current application. The seizures manifest in “stunned” posture associated with rearing, forelimb, automatic movements and clonus, twitching the vibrissae and Straub–tail. The duration of the seizure activity ranges from 60 to 120 s in untreated animals. At the end of the seizure, animals resume their normal exploratory behavior. The experimental end point is protection against the seizure. The animal is considered to be protected if it resumes its normal exploratory behavior within 10 s from the stimulation (Brown et al., 1953).

In vitro studies–sodium channel binding assay

The radioligand binding studies were performed commercially in Cerep Laboratories (Poitiers, France) using testing procedures described in detail elsewhere (Brown, 1986). The general information is listed in Table 6.

Table 6.

Experimental conditions—Na+ channel (site 2) binding assays

Source Ligand Concentration Kd Nonspecific binding Incubation Detection method
Rat cerebral cortex [3H] Batrachotoxin 10 nM 91 nM Veratridine (300 μM) 60 min 37 °C Scintillation counting
Open in a new tab

Conclusion

In the current studies, the library of twenty-two new N-phenyl-2-(4-phenylpiperazin-1-yl)acetamide derivatives has been synthesized and evaluated for their anticonvulsant activity in the maximum electroshock (MES) and scPTZ seizure tests. The results of in vivo pharmacological studies showed activity exclusively in the MES seizures especially for 3-(trifluoromethyl)anilide derivatives, whereas majority of 3-chloroanilide analogs were inactive. Several molecules showed activity in the 6-Hz screen that may indicate their potential usefulness in partial and therapy-resistant epilepsy. The pharmacophoric role of the pyrrolidine-2,5-dione ring for anticonvulsant properties was proved.

Acknowledgments

The authors wish to thank the Antiepileptic Drug Development Program (Epilepsy Branch, National Institute of Neurological Disorders and Stroke, National Institute of Health, Rockville, MD, USA), for pharmacological data. We are also grateful to Professor Katarzyna Kieć-Kononowicz (Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Kraków, Poland) the coordinator of the ADD Program from Polish site and Mr. Janusz Górecki for the synthesis of several compounds.

Conflict of interest

The authors declare no conflict of interest.

References

  1. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47(3):217–227. doi: 10.1016/S0920-1211(01)00302-3. [DOI] [PubMed] [Google Scholar]
  2. Beguin C, Andurkar SV, Jin AY, Stables JP, Weaver DF, Kohn H. Functionalized amido ketones: new anticonvulsant agents. Bioorg Med Chem. 2003;11(19):4275–4285. doi: 10.1016/S0968-0896(03)00434-6. [DOI] [PubMed] [Google Scholar]
  3. Bell GS, Sander JW. The epidemiology of epilepsy: the size of the problem. Seizure. 2002;11(Suppl A):306–314. [PubMed] [Google Scholar]
  4. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the eight Eilat conference (EILAT VIII) Epilepsy Res. 2007;73(1):1–52. doi: 10.1016/j.eplepsyres.2006.10.008. [DOI] [PubMed] [Google Scholar]
  5. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White S. Progress report on new antiepileptic drugs: a summary of the ninth Eilat conference (EILAT IX) Epilepsy Res. 2009;83(1):1–43. doi: 10.1016/j.eplepsyres.2008.09.005. [DOI] [PubMed] [Google Scholar]
  6. Brown GB. 3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin. J Neurosci. 1986;6(7):2064–2070. doi: 10.1523/JNEUROSCI.06-07-02064.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brown WC, Schiffman DO, Swinyard EA, Goodman LS. Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther. 1953;107(3):273–283. [PubMed] [Google Scholar]
  8. Bruno-Blanch L, Gálvez J, Garcia-Domenach R. Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity. Bioorg Med Chem Lett. 2003;13(16):2749–2754. doi: 10.1016/S0960-894X(03)00535-3. [DOI] [PubMed] [Google Scholar]
  9. Catterall WA, Morrow CS, Daly JW, Brown GB. Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem. 1981;256(17):8922–8927. [PubMed] [Google Scholar]
  10. Chang BS, Lowenstein DH. Epilepsy. N Eng J Med. 2003;349(13):1257–1266. doi: 10.1056/NEJMra022308. [DOI] [PubMed] [Google Scholar]
  11. Dunham NW, Miya TA. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc. 1957;46(3):208–209. doi: 10.1002/jps.3030460322. [DOI] [PubMed] [Google Scholar]
  12. Ghidini E, Delcanale M, De Fanti R, Rizzi A, Mazzuferi M, Rodi D, Simonato M, Lipreri M, Bassani F, Battipaglia L, Bergamaschi M, Villetti G. Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives. Bioorg Med Chem. 2006;14(10):3263–3274. doi: 10.1016/j.bmc.2005.12.064. [DOI] [PubMed] [Google Scholar]
  13. Hadjipavlou-Litina D. Review, reevaluation, and new results in quantitative structure-activity studies of anticonvulsants. Med Res Rev. 1998;18(2):91–119. doi: 10.1002/(SICI)1098-1128(199803)18:2<91::AID-MED1>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  14. Hen H, Bialer M, Wlodarczyk B, Finnell RF, Yagen B. Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. J Med Chem. 2010;53(10):4177–4186. doi: 10.1021/jm100170w. [DOI] [PubMed] [Google Scholar]
  15. Ismail FMD. Important fluorinated drugs in experimental and clinical use. J Fluorine Chem. 2002;118(1–2):27–1033. doi: 10.1016/S0022-1139(02)00201-4. [DOI] [Google Scholar]
  16. Kamiński K, Rzepka S. Obniska J (2011) Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones. Bioorg Med Chem Lett. 2011;21(19):5800–5803. doi: 10.1016/j.bmcl.2011.07.118. [DOI] [PubMed] [Google Scholar]
  17. Kamiński K, Obniska J, Wiklik B, Atamanyuk D. Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs. Eur J Med Chem. 2011;46(9):4634–4641. doi: 10.1016/j.ejmech.2011.07.043. [DOI] [PubMed] [Google Scholar]
  18. Kamiński K, Obniska J, Chlebek I, Liana P, Pękala E. Synthesis and biological properties of new N-Mannich bases derived from 3-methyl-3-phenyl- and 3,3-dimethyl-succinimides Part V. Eur J Med Chem. 2013;66:12–21. doi: 10.1016/j.ejmech.2013.05.011. [DOI] [PubMed] [Google Scholar]
  19. Kamiński K, Wiklik B, Obniska J. Synthesis, anticonvulsant properties, and SAR analysis of differently substituted pyrrolidine-2,5-diones and piperidine-2,6-diones. Arch Pharm Chem Life Sci. 2014;347:1–13. doi: 10.1002/ardp.201300231. [DOI] [PubMed] [Google Scholar]
  20. Khan HN, Kulsoom S, Rashid H. Ligand based pharmacophore model development for the identification of novel antiepileptic compound. Epilepsy Res. 2012;98(1):62–71. doi: 10.1016/j.eplepsyres.2011.08.016. [DOI] [PubMed] [Google Scholar]
  21. Kirk KL. Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules. J Fluorine Chem. 2006;127(8):1013–1027. doi: 10.1016/j.jfluchem.2006.06.007. [DOI] [Google Scholar]
  22. Krall RL, Penry K, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: II Anticonvulsant drug screening. Epilepsia. 1978;19(4):409–428. doi: 10.1111/j.1528-1157.1978.tb04507.x. [DOI] [PubMed] [Google Scholar]
  23. Kupferberg HJ. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia. 1989;30(Suppl. 1):S51–S56. doi: 10.1111/j.1528-1157.1989.tb05815.x. [DOI] [PubMed] [Google Scholar]
  24. Liu G, Yarov-Yarovoy V, Nobbs M, Clare JJ, Scheuer T, Catterall WA. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacol. 2003;44(3):413–422. doi: 10.1016/S0028-3908(02)00400-8. [DOI] [PubMed] [Google Scholar]
  25. Łuszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61(2):197–216. doi: 10.1016/S1734-1140(09)70024-6. [DOI] [PubMed] [Google Scholar]
  26. Malawska B. New anticonvulsant agents. Curr Top Med Chem. 2005;5(1):69–85. doi: 10.2174/1568026053386944. [DOI] [PubMed] [Google Scholar]
  27. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002;45(2):312–320. doi: 10.1021/jm0109199. [DOI] [PubMed] [Google Scholar]
  28. Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ. Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther. 1984;228(2):523–530. [PubMed] [Google Scholar]
  29. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4(1):18–61. doi: 10.1016/j.nurt.2006.11.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Morieux P, Stables JP, Kohn H. Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives. Bioorg Med Chem. 2008;16(19):8968–8975. doi: 10.1016/j.bmc.2008.08.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Obniska J, Zagórska A. Synthesis and anticonvulsant properties of new N-[(4-arylpiperazin-1-yl)-methyl] derivatives of 3-aryl pyrrolidine-2,5-dione and 2-aza-spiro[4.4]nonane-1,3-dione. Il Farmaco. 2003;58(12):1227–1234. doi: 10.1016/S0014-827X(03)00187-3. [DOI] [PubMed] [Google Scholar]
  32. Obniska J, Kamiński K, Zagórska A, Dzierzawska-Majewska A, Karolak-Wojciechowska J. Synthesis and anticonvulsant activity of new fluorinated N-phenyl- and N-benzyl-2-azaspiro[4.4]nonane- and [4.5]decane-1,3-dione derivatives: part III. J Fluorine Chem. 2006;127(3):417–425. doi: 10.1016/j.jfluchem.2006.01.009. [DOI] [Google Scholar]
  33. Obniska J, Kopytko M, Zagórska A, Chlebek I, Kamiński K. Synthesis and anticonvulsant properties of new Mannich bases derived from 3-aryl-pyrrolidine-2,5-diones. Part 1. Arch Pharm. 2010;343(6):333–341. doi: 10.1002/ardp.200900250. [DOI] [PubMed] [Google Scholar]
  34. Obniska J, Chlebek I, Kamiński K, Karolak-Wojciechowska J. Synthesis and anticonvulsant properties of new N-Mannich bases derived from 3,3-diphenyl- and 3-ethyl-3-methyl-pyrrolidine-2,5-diones. Part III. Arch Pharm. 2013;346(1):71–82. doi: 10.1002/ardp.201200265. [DOI] [PubMed] [Google Scholar]
  35. Rogawski MA. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res. 2006;68(1):22–28. doi: 10.1016/j.eplepsyres.2005.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5(7):553–564. doi: 10.1038/nrn1430. [DOI] [PubMed] [Google Scholar]
  37. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990;42(3):223–286. [PubMed] [Google Scholar]
  38. Smart BE. Fluorine substituent effects (on bioactivity) J Fluorine Chem. 2001;109(1):3–11. doi: 10.1016/S0022-1139(01)00375-X. [DOI] [Google Scholar]
  39. Song B, Yang S, Zhong H, Jin L, Hu D, Liu G. Synthesis and bioactivity of 2-cyanoacrylates containing a trifluoromethylphenyl moiety. J Fluorine Chem. 2005;126(1):87–92. doi: 10.1016/j.jfluchem.2004.10.041. [DOI] [Google Scholar]
  40. Willow M, Catterall WA. Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol. 1982;22(3):627–635. [PubMed] [Google Scholar]
  41. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol. 1984;25(2):228–234. [PubMed] [Google Scholar]
  42. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol. 1985;27(5):549–558. [PubMed] [Google Scholar]
  43. Wong MG, Defina JA, Andrews PR. Conformational analysis of clinically active anticonvulsant drugs. J Med Chem. 1986;29(4):562–572. doi: 10.1021/jm00154a022. [DOI] [PubMed] [Google Scholar]
  44. World Health Organization (2010) Epilepsy: key facts. Available at: www.who.int/mediacentre/factsheets/fs999/en

Articles from Medicinal Chemistry Research are provided here courtesy of Springer

RESOURCES